Atypical antipsychotics and glucose homeostasis

Journal of Clinical Psychiatry

Volumn 66, Issue 4, 2005, Pages 504-514

  Bergman, Richard N ^a   Ader, Marilyn ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; GLUCOSE; INSULIN; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ANIMAL MODEL; ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DOG; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HORMONE ACTION; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LIPID STORAGE; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PATHOGENESIS; PEER REVIEW; PRIORITY JOURNAL; SIDE EFFECT; SITTING; VALIDATION PROCESS; WEIGHT GAIN;

EID: 17844403749     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0414     Document Type: Article

References (87)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-787
2. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. Diabetes Care 1998;21:518-524
3. Seidell JC. Obesity, insulin resistance and diabetes: a worldwide epidemic. Br J Nutr 2000;83(suppl 1):S5-S8
4. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001;286:1195-1200
5. American Diabetes Association. How to Tell if You Have Pre-Diabetes. Available at: http://www.diabetes.org/pre-diabetes/pre-diabetes-symptoms.jsp. Accessed March 2, 2005
6. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343:230-238
7. Atkinson MA, Maclaren NK. Islet cell autoantigens in insulin-dependent diabetes. J Clin Invest 1993;92:1608-1616
8. Weir GC, Leahy JL, Bonner-Weir S. Experimental reduction of B-cell mass: implications for the pathogenesis of diabetes. Diabetes Metab Rev 1986;2:125-161
9. Myers M, Mackay I, Rowley M, et al. Dietary microbial toxins and type 1 diabetes: a new meaning for seed and soil. Diabetologia 2001;44:1199-1200
10. Antonelli A, Tuomi T, Nannipieri M, et al. Autoimmunity to CD38 and GAD in Type I and Type II diabetes: CD38 and HLA genotypes and clinical phenotypes. Diabetologia 2002;45:1298-1306
11. Umpaichitra V, Banerji MA, Castells S. Autoantibodies in children with type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2002;15 (suppl 1):525-530
12. Kaufman FR. Type 2 diabetes in children and youth. Rev Endocr Metab Disord 2003;4:33-42
13. Arner P, Pollare T, Lithell H. Different aetiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia 1991;34:483-487
14. Taniguchi A, Nakai Y, Fukushima M, et al. Pathogenic factors responsible for glucose intolerance in patients with NIDDM. Diabetes 1992;41:1540-1546
15. Shen SW, Reaven GM, Farquhar JW. Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest 1970;49:2151-2160
16. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-312
17. Berg AH, Combs TP, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-953
18. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993;259:87-91
19. Mora S, Pessin JE. An adipocentric view of signaling and intracellular trafficking. Diabetes Metab Res Rev 2002;18:345-356
20. Nurjhan N, Consoli A, Gerich JE. Increased lipolysis and its consequences on gluconeogenesis in non-insulin-dependent diabetes mellitus. J Clin Invest 1992;89:169-175
21. Bevilacqua S, Bonadonna R, Buzzigoli G, et al. Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. Metabolism 1987;36:502-506
22. Ferrannini E, Barrett EJ, Bevilacqua S, et al. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983;72:1737-1747
23. Burks DJ, White MF. IRS proteins and beta-cell function. Diabetes 2001;50(suppl 1):S140-S145
24. Donath MY, Storling J, Maedler K, et al. Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med 2003;81:455-470
25. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med 1993;329:1988-1992
26. Martin BC, Warram JH, Rosner B, et al. Familial clustering of insulin sensitivity. Diabetes 1992;41:850-854
27. Bogardus C, Lillioja S, Nyomba BL, et al. Distribution of in vivo insulin action in Pima Indians as mixture of three normal distributions. Diabetes 1989;38:1423-1432
28. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000;106:473-481
29. Carey DG, Jenkins AB, Campbell LV, et al. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996;45:633-638
30. Kim SP, Ellmerer M, van Citters GW, et al. Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric, moderate-fat diet in the dog. Diabetes 2003;52:2453-2460
31. Kissebah AH. Central obesity, measurement and metabolic effects. Diabet Rev 1997;5:8-20
32. Mittelman SD, van Citters GW, Kim SP, et al. The longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced β-cell response. Diabetes 2000;49:2116-2125
33. Clement K, Vaisse C, Manning B, et al. Genetic variation in the β3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 1995;333:352-354
34. Hong Y, Rice T, Gagnon J, et al. Familial clustering of insulin and abdominal visceral fat: the HERITAGE family study. J Clin Endocrinol Metab 1998;83:4239-4245
35. Bergman RN, Ader M, Huecking K, et al. Accurate assessment of β-cell function: the hyperbolic correction. Diabetes 2001;51 (suppl 1):S212-S220
36. Weyer C, Hanson K, Bogardus C, et al. Long-term changes in insulin action and insulin secretion associated with gain, loss, regain and maintenance of body weight. Diabetologia 2000;43:36-46
37. Elbein SC, Wegner K, Kahn SE. Reduced beta-cell compensation to the insulin resistance associated with obesity in members of Caucasian familial type 2 diabetic kindreds. Diabetes Care 2000;23:221-227
38. Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 2002;32(suppl 3):35-45
39. Xiang A, Peters RK, Trigo E, et al. Multiple metabolic defects during late pregnancy in women at high risk for type 2 diabetes mellitus. Diabetes 1999;48:848-854
40. Bergman RN, Watanabe R, Rebrin K, et al. Toward an integrated phenotype in pre-NIDDM. Diabet Med 1996;13:S67-S77
41. Larsson H, Ahren B. Failure to adequately adapt to reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance. Diabetologia 1996;39:1099-1107
42. Weir GC. Non-insulin dependent diabetes mellitus: interplay between β-cell inadequacy and insulin resistance. Am J Med 1982;73:461-464
43. Buchanan TA, Xiang AH, Peters RK, et al. Response of pancreatic β-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes 2000;49:782-788
44. Thakore JH, Mann JN, Vlahos I, et al. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002;26:137-141
45. Zhang ZJ, Yao ZJ, Liu Y, et al. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Br J Psychiatry 2004;184:58-62
46. Hughes JR, Hatsukami DK, Mitchell JE, et al. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986;143:993-997
47. Attvall S, Fowelin J, Lager I, et al. Smoking induces insulin resistance: a potential link with the insulin resistance syndrome. J Intern Med 1993;233:327-332
48. Jo YH, Talmage DA, Role LW. Nicotinic receptor-mediated effects on appetite and food intake. J Neurobiol 2002;53:618-632
49. Eliasson B, Attvall S, Taskinen MR, et al. Smoking cessation improves insulin sensitivity in healthy middle-aged men. Eur J Clin Invest 1997;27:450-456
50. Jessen AB, Toubro S, Astrup A. Effect of chewing gum containing nicotine and caffeine on energy expenditure and substrate utilization in men. Am J Clin Nutr 2003;77:1442-1447
51. Stumvoll M, Haring H, Fritsche A. For debate: Starling's curve of the pancreas: overuse of a concept? Horm Metab Res 2003;35:391-395
52. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002;122:531-544
53. Hampton SM, Morgan LM, Tredger JA, et al. Insulin and C-peptide levels after oral and intravenous glucose: contribution of enteroinsular axis to insulin secretion. Diabetes 1986;35:612-616
54. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000;26:903-912
55. Mahtani MM, Widen E, Lehto M, et al. Mapping of a gene for type 2 diabetes associated with an insulin secretion defect by a genome scan in Finnish families. Nat Genet 1996;13:90-94
56. Rich SS, Bowden DW, Haffner SM, et al. Identification of quantitative trait loci for glucose homeostasis: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes 2004;53:1866-1875
57. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696
58. Goodnick PJ, Jerry JM. Aripiprazole: profile on efficacy and safety. Expert Opin Pharmacother 2002;3:1773-1781
59. Mayer-Davis EJ, Levin S, Bergman RN, et al. Insulin secretion, obesity, and potential behavioral influences: results from the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Metab Res Rev 2001;17:137-145
60. Hartfield AW, Moore NA, Clifton PG. Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat. Psychopharmacology (Berl) 2003;167:115-122
61. Ota M, Mori K, Nakashima A, et al. Peripheral injection of risperidone, an atypical antipsychotic, alters the body weight gain of rats. Clin Exp Pharmacol Physiol 2002;29:980-989
62. Baptista T, Araujo de Baptista E, Ying Kin NM, et al. Comparative effects of the antipsychotics sulpiride or risperidone in rats, 1: bodyweight, food intake, body composition, hormones and glucose tolerance. Brain Res 2002;957:144-151
63. Pouzet B, Mow T, Kreilgard M, et al. Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav 2003;75:133-140
64. Virkkunen M, Wahlbeck K, Rissanen A, et al. Decrease of energy expenditure causes weight increase in olanzapine treatment: a case study. Pharmacopsychiatry 2002;35:124-126
65. Burkholder WJ, Thatcher CD. Validation of predictive equations for use of deuterium oxide dilution to determine body composition of dogs. Am J Vet Res 1998;59:927-937
66. Muller MJ, Bosy-Westphal A, Kutzner D, et al. Metabolically active components of fat-free mass and resting energy expenditure in humans: recent lessons from imaging technologies. Obes Res 2002;3:113-122
67. Ryan MCM, Flanagan S, Kinsella U, et al. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004;74:1999-2008
68. Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl) 2003;170:157-166
69. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents. Arch Gen Psychiatry 2005;62:19-28
70. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419
71. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-2410
72. Cohn T, Remington G, Leiter L, et al. Antipsychotic medication and insulin resistance. In: Proceedings of the 8th International Congress on Schizophrenia Research; April 29-May 2, 2001; Whistler, British Columbia, Canada
73. Berry S, Lange DS, Mahmoud RA. Normalization of olanzapine-associated abnormalities of insulin resistance and insulin release after switch to risperidone. In: Proceedings of the 40th Annual Meeting of the American College of Neuropsychopharmacology; Dec 9-13, 2001; Waikoloa, Hawaii
74. Ryan MCM, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284-289
75. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-1057
76. Breda E, Cavaghan MK, Toffolo G, et al. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes 2001;50:150-158
77. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337-345
78. Baptista T, Lacruz A, Angeles F, et al. Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration. Pharmacopsychiatry 2001;34:223-231
79. Horowitz M, Edelbroek MA, Wishart JM, et al. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993;36:857-862
80. Bergman RN. Lilly Lecture 1989. Toward physiological understanding of glucose tolerance: minimal-model approach. Diabetes 1989;38:1512-1527
81. Dive A, Foret F, Jamart J, et al. Effect of dopamine on gastrointestinal motility during critical illness. Intensive Care Med 2000;26:901-907
82. Avram AM, Patel V, Taylor HC, et al. Euglycemic clamp study in clozapine-induced diabetic ketoacidosis. Ann Pharmacother 2001;35:1381-1387
83. Sowell M, Mukhopadhyay N, Cavazzoni P, et al. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab 2003;88:5875-5880
84. Sowell MO, Mukhopadhyay N, Cavazzoni P, et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 2002;87:2918-2923
85. Ader M, Kim SP, Catalano KJ, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005;54:862-871
86. Lillioja S, Bogardus C. Obesity and insulin resistance: lessons learned from the Pima Indians. Diabetes Metab Rev 1988;5:517-540
87. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601